CJC-1295 – No DAC 10mg

CJC-1295 No DAC 10mg is suited for laboratories and research teams investigating GHRH analog structure-activity relationships. It supports studies examining peptide-receptor binding dynamics at the pituitary level, pulsatile signaling kinetics, and molecular stability profiles under controlled experimental conditions. Research teams designing multi-week preclinical protocols benefit from the 10mg concentration, which reduces vial turnover and ensures consistent peptide availability across extended observation periods. Produced by Elivena in USA GMP-certified facilities, each vial is verified by COA for sequence identity and purity.

For laboratory research use only. Not approved by FDA or EMA. Every batch includes a Certificate of Analysis confirming purity and identity.

Molecular Stability and Degradation Kinetics

The No DAC configuration provides researchers with a structurally defined model for examining peptide degradation rates, plasma stability profiles, and half-life kinetics under various experimental conditions. Studies investigating the effect of molecular modifications on GHRH analog stability use CJC-1295 No DAC as a reference compound for comparative structural analysis.

Pulsatile Signaling Kinetics

The compound’s shorter duration of action makes it a preferred model for studying pulsatile peptide-receptor interaction patterns. Researchers examining the timing, amplitude, and frequency of GHRH receptor activation use this analog to characterize signaling kinetics in cell-based and preclinical in-vivo models. Paired with Ipamorelin in combination protocols, it enables investigation of complementary receptor pathway interactions.

GHRH Receptor Interaction Modeling

CJC-1295 No DAC supports in-vitro and preclinical studies examining the structure-activity relationship of GHRH analogs at the pituitary receptor level. Researchers characterizing binding affinity, receptor selectivity, and downstream cAMP pathway activation utilize this compound for its well-defined molecular profile and high purity grade.

Preparation Guidelines

Reconstitute lyophilized CJC-1295 No DAC 10mg with sterile bacteriostatic water using standard laboratory technique. Typical reconstitution volumes in research settings range from 1–2ml depending on experimental concentration requirements. Use sterile equipment for all handling and preparation steps.

Storage Conditions

Store lyophilized peptide at 2–8°C, protected from light and moisture, prior to reconstitution. Following reconstitution, maintain refrigeration at 2–8°C and use within the timeframe specified in your laboratory protocol. Lyophilized material does not require cold-chain shipping but should be refrigerated upon receipt to maximize stability. Each Elivena vial is supplied with handling guidance and COA documentation.

Pharmaceutical-Grade Manufacturing by Elivena

Manufactured by Elivena in USA GMP-compliant facilities, CJC-1295 No DAC 10mg achieves approximately 99% purity confirmed by independent third-party testing. Each vial includes COA documentation verifying peptide sequence, purity grade, and identity. This level of characterization supports reproducible, high-quality preclinical research requiring precisely defined GHRH analog material.

• CAS: 863288-34-0
• Chemical Formula: C₁₅₂H₂₅₂N₄₄O₄₂
• Molecular Weight: 3367.9 g/mol
• Peptide Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg
• Synonyms: MOD-GRF(1-29), CJC-1295 without DAC, modgrf, tetrasubstituted grf, modified grf
• Shelf life: 24 months from the manufacturing date.

GHRH Analog Structural Profile

CJC-1295 No DAC is a synthetic analog of growth hormone-releasing hormone (GHRH), a naturally occurring peptide originating in the hypothalamus. The No DAC configuration — meaning without a Drug Affinity Complex — produces a shorter plasma half-life compared to the DAC variant. This shorter half-life makes it a well-characterized model for studying pulsatile receptor activation kinetics and time-dependent signaling patterns in pituitary model systems. Its defined structural profile supports reproducible molecular interaction studies.

Receptor Binding and Signaling Pathway Investigation

CJC-1295 No DAC is studied for its binding affinity to GHRH receptors and the downstream intracellular signaling cascades this interaction initiates. Researchers use this compound to examine receptor occupancy dynamics, signal transduction pathway activity, and feedback inhibition mechanisms in controlled preclinical models. Its peptide hormone structure enables investigation of GHRH receptor interaction at a molecular level, distinct from exogenous hormone administration paradigms.

Pharmaceutical-Grade Manufacturing by Elivena

Manufactured by Elivena in USA GMP-compliant facilities, CJC-1295 No DAC 10mg achieves approximately 99% purity confirmed by independent third-party testing. Each vial includes COA documentation verifying peptide sequence, purity grade, and identity. This level of characterization supports reproducible, high-quality preclinical research requiring precisely defined GHRH analog material.

The DAC (Drug Affinity Complex) modification extends the compound’s plasma half-life by enabling albumin binding, resulting in prolonged receptor exposure. The No DAC version lacks this modification, producing a shorter half-life and more defined pulsatile activation kinetics. Researchers select between variants based on the temporal resolution requirements of their signaling or receptor interaction study design.

Research protocols commonly use 1–2ml of sterile bacteriostatic water per 10mg vial, yielding concentrations appropriate for a range of in-vitro and preclinical applications. Specific concentration requirements depend on the experimental design and endpoint being measured.

CJC-1295 No DAC is frequently paired with Ipamorelin in preclinical studies to investigate complementary GHRH and ghrelin receptor pathway interactions. Combination protocols allow researchers to examine additive or synergistic signaling activity across distinct receptor systems in controlled experimental models.